
When used as a supplement to an elevated PSA reading, a new urine test that detects instances of a specific genetic anomaly and the presence of the PCA3 marker can help men delay or avoid biopsy while identifying patients at the highest risk for clinically significant prostate cancer, the authors of a recently published study report.